Early research (Phase 1)Ended earlyNCT05069935What this trial is testingFT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsWho this might be right forSolid Tumor, Adult Fate Therapeutics 16
Not applicableLooking for participantsNCT06867484What this trial is testingBreast Re-irradiation After Second Ipsilateral LumpectomyWho this might be right forBreast CancerCancerCancer of the Breast+3 more Youssef Zeidan 114
Testing effectiveness (Phase 2)Ended earlyNCT01938833What this trial is testingRomidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerWho this might be right forHER2-negative Breast CancerInflammatory Breast CancerMale Breast Cancer+2 more Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 9
Testing effectiveness (Phase 2)Study completedNCT00733408What this trial is testingNab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerWho this might be right forEstrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+3 more University of Washington 59
Not applicableStudy completedNCT02752893What this trial is testingEstrogen Receptor-Positive Breast Cancer Patient-Derived XenograftsWho this might be right forBreast Cancer Dartmouth-Hitchcock Medical Center 10
Testing effectiveness (Phase 2)Study completedNCT02048059What this trial is testingANG1005 in Breast Cancer Patients With Recurrent Brain MetastasesWho this might be right forBreast CancerBrain Metastases Angiochem Inc 72
Testing effectiveness (Phase 2)Looking for participantsNCT07380646What this trial is testingThe Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast CancerWho this might be right forLeucogenRibociclibNeutropenia (Low White Blood Cell Count)+1 more Second Affiliated Hospital, Zhejiang University, School of Medicine 94
Testing effectiveness (Phase 2)Looking for participantsNCT07471776What this trial is testingStudy on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast CancerWho this might be right forMetastatic Breast Cancer ( HER2 Negative) Fudan University 45
Large-scale testing (Phase 3)Active Not RecruitingNCT05889390What this trial is testingNeoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast CancerWho this might be right forHER2-negative Breast Cancer Semmelweis University 71
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625What this trial is testingNeoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsWho this might be right forUntreated Early-stage or Locally Advanced Breast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)Ended earlyNCT04933227What this trial is testingExplore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)Who this might be right forStomach NeoplasmsGastric CancerGastroesophageal Junction Adenocarcinoma Hoffmann-La Roche 29
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496What this trial is testingCapivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerWho this might be right forLocally Advanced (Inoperable) or Metastatic Breast Cancer AstraZeneca 818
Testing effectiveness (Phase 2)Active Not RecruitingNCT06957379What this trial is testingSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyWho this might be right forHR+/HER2- Advanced/Metastatic Breast Cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 78
Testing effectiveness (Phase 2)Study completedNCT01031446What this trial is testingCisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast CancerWho this might be right forBreast Cancer Vanderbilt-Ingram Cancer Center 55
Not applicableUnknownNCT06344780What this trial is testingAbemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast CancerWho this might be right forBreast Cancer Fudan University 200
Early research (Phase 1)Active Not RecruitingNCT05509790What this trial is testingLY3484356 in Chinese Participants With Advanced Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 17
Not applicableTemporarily pausedNCT02993068What this trial is testingStand up to Cancer: MAGENTA (Making Genetic Testing Accessible)Who this might be right forBARD1 Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+12 more M.D. Anderson Cancer Center 5,200
Not applicableStudy completedNCT04736576What this trial is testingStudy to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine MonotherapyWho this might be right forBreast Cancer Pfizer 99
Large-scale testing (Phase 3)Study completedNCT00003440What this trial is testingPaclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or MetastaticWho this might be right forHER2-negative Breast CancerHER2-positive Breast CancerRecurrent Breast Cancer+2 more National Cancer Institute (NCI) 580
Testing effectiveness (Phase 2)Ended earlyNCT02120417What this trial is testingRuxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerWho this might be right forBreast Cancer Incyte Corporation 149